SCI时时刷

search
+
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Among the most common molecular alterations detected in non-small-cell lung cancer (NSCLC) are mutations in Kristen Rat Sa...
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
The most recently approved biologics for moderate-to-severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Dr...
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders
The sirtuin family is a heterogeneous group of proteins that play a critical role in many cellular activities. Several deg...
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
Topical ruxolitinib 1.5% cream (Opzelura®), a Janus kinase (JAK) inhibitor, is the first treatment to be approved in ...
Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain
Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain
An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate [Myfembree®...
The Pharmacological Landscape for Fatty Change of the Pancreas
The Pharmacological Landscape for Fatty Change of the Pancreas
The quest for medications to reduce intra-pancreatic fat deposition is now quarter a century old. While no specific medica...
Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease
Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease
Perfluorohexyloctane ophthalmic solution (Miebo®) is a single-entity, water-, steroid- and preservative-free, first-i...
Dimdazenil: First Approval
Dimdazenil: First Approval
Dimdazenil (Junoenil®) is a small-molecule, oral, partial positive allosteric modulator of the gamma-aminobutyric aci...
Danicopan: First Approval
Danicopan: First Approval
Danicopan (Voydeya®) is an oral complement factor D inhibitor that is being developed by Alexion AstraZeneca Rare Dis...
Iptacopan: First Approval
Iptacopan: First Approval
Iptacopan (FABHALTA®) is an oral complement Factor B inhibitor developed by Novartis Pharmaceuticals for the treatmen...
Fidanacogene Elaparvovec: First Approval
Fidanacogene Elaparvovec: First Approval
Fidanacogene elaparvovec (PrBEQVEZ™) is an adeno-associated viral (AAV) vector-based gene therapy developed by Spark...
Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials
Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials
Nonalcoholic fatty liver disease (NAFLD), currently referred to as metabolic dysfunction-associated steatotic liver diseas...
Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability
Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability
Currently, there are four monoclonal antibodies (mAbs) that target the cluster of differentiation (CD) 20 receptor availab...
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?
Tamoxifen, a cornerstone in the adjuvant treatment of estrogen receptor-positive breast cancer, significantly reduces brea...
Opioids for Acute Musculoskeletal Pain: A Systematic Review with Meta-Analysis
Opioids for Acute Musculoskeletal Pain: A Systematic Review with Meta-Analysis
To evaluate the efficacy of opioids for people with acute musculoskeletal pain against placebo. Systematic review and meta...
Adult-Onset Still’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options
Adult-Onset Still’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options
Adult-onset Still’s disease (AOSD) is a multisystemic complex disorder clinically characterised by episodes of spiki...
Aponermin: First Approval
Aponermin: First Approval
Aponermin (沙艾特) is a recombinant circularly permuted human tumour necrosis factor-related apoptosis-i...
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection
SER-109 (VOWST™; fecal microbiota spores, live-brpk) is a live biotherapeutic product indicated to prevent the recur...
A Neuroanatomic and Pathophysiologic Framework for Novel Pharmacological Approaches to the Treatment of Post-traumatic Stress Disorder
A Neuroanatomic and Pathophysiologic Framework for Novel Pharmacological Approaches to the Treatment of Post-traumatic Stress Disorder
Post-traumatic stress disorder (PTSD) is a debilitating disorder inflicting high degrees of symptomatic and socioeconomic ...
Eplontersen: First Approval
Eplontersen: First Approval
Eplontersen (Wainua™) is a ligand-conjugated antisense oligonucleotide directed to TTR, which is being developed by ...
Apadamtase Alfa: First Approval
Apadamtase Alfa: First Approval
Apadamtase alfa (ADAMTS13, recombinant-krhn; ADZYNMA), a human recombinant form of a disintegrin and metalloproteinase wit...
Nirogacestat: First Approval
Nirogacestat: First Approval
Nirogacestat (OGSIVEO™) is an oral, selective, reversible, small molecule γ-secretase inhibitor developed by Sp...
Berdazimer Topical Gel, 10.3%: First Approval
Berdazimer Topical Gel, 10.3%: First Approval
Berdazimer topical gel, 10.3% (ZELSUVMI™) is a nitric oxide (NO) releasing topical gel developed by Novan Inc. (a Li...
Vonoprazan: A Review in Helicobacter pylori Infection
Vonoprazan: A Review in Helicobacter pylori Infection
Treatment for the eradication of Helicobacter pylori infection, a leading cause of peptic ulcer disease and an important r...
Etrasimod: First Approval
Etrasimod: First Approval
Etrasimod (VELSIPITY™) is an orally available, small-molecule selective sphingosine-1-phosphate (S1P) receptor modul...
Tirzepatide: A Review in Type 2 Diabetes
Tirzepatide: A Review in Type 2 Diabetes
Tirzepatide (Mounjaro®), a first-in-class dual incretin agonist of the glucose-dependent insulinotropic polypeptide (...
Lebrikizumab: First Approval
Lebrikizumab: First Approval
Lebrikizumab (Ebglyss®) is a subcutaneous recombinant humanized IgG4 anti-IL-13 monoclonal antibody developed by Almi...
Capivasertib: First Approval
Capivasertib: First Approval
Capivasertib (Truqap™) is an orally available, small-molecule pan-AKT inhibitor being developed by AstraZeneca for t...
Repotrectinib: First Approval
Repotrectinib: First Approval
Repotrectinib (AUGTYRO™) is a next-generation, oral, small-molecule kinase inhibitor of proto-oncogene tyrosine-prot...
Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature
Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature
Increased plasma levels of low-density lipoprotein cholesterol (LDL-C) are causally associated with atherosclerotic cardio...
阅读更多
format_indent_increase